ArticleMicrobiology spectrum2025
Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam.
Michelle Nägeli, Shade Rodriguez, Aimee Iradukunda, Abigail L Manson, Ashlee M Earl, Thea Brennan-Krohn
Abstract read
In one paragraphArticle in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
6 authors.
Michelle Nägeli *Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Shade Rodriguez *Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Aimee IradukundaDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Abigail L MansonInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0002-3800-0714 Ashlee M EarlInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.ORCID 0000-0001-7857-9145 Thea Brennan-KrohnDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID 0000-0002-1284-0643 Funding
Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI CUOMO, CHRISTINA A · 2014 to 2024
$66.5MSusceptibility and resistance of multidrug-resistant gram-negative bacteria to novel beta-lactam/beta-lactamase inhibitor combinationsR01AI178875 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BRENNAN-KROHN, THEA · 2023 to 2024
$951kAntimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae - Administrative SupplementK08AI132716 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BRENNAN-KROHN, THEA · 2018 to 2022
$916kNational Institute of Allergy and Infectious Diseases K08AI132716National Institute of Allergy and Infectious Diseases R01AI178875National Institute of Allergy and Infectious Diseases U19AI110818NIAID NIH HHS K08 AI132716NIAID NIH HHS R01 AI178875NIAID NIH HHS U19 AI110818
6 · The paper itselfAbstract
Avibactam (AVI) is a diazabicyclooctane (DBO) β-lactamase inhibitor used clinically in combination with ceftazidime. At concentrations higher than those typically achieved
Indexed as
Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsBacterial Proteinsbeta-LactamasesDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsMutationPenicillin-Binding ProteinsWhole Genome SequencingAnti-Bacterial AgentsavibactamAzabicyclo CompoundsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesPenicillin-Binding Proteinsantibiotic resistanceantimicrobial resistanceavibactamdiazabicyclooctanegram-negative bacteriapenicillin-binding proteins
Identifiers
PMID40503840
PMCPMC12323667
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390